Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

46.00 +0.57 (+1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Cash-Producing Stock to Research Further and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Healthcare Stocks on Our Watchlist and 1 We Avoid
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Headwinds
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Integer Holdings, Astrana Health, Surgery Partners, IQVIA, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy
1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation
Supernus Pharmaceuticals (SUPN) offers strong growth, solid profitability, and fair valuations, making it an ideal pick for Affordable Growth investors. 
Via Chartmill
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media... 
Via StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 14.4% in the afternoon session after the company posted strong second-quarter earnings that beat expectations... 
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday afternoon. Here’s what investors should know. 
Via StockStory
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to... 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 3.1% in the morning session after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its... 
Via StockStory
Topics Lawsuit
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus Pharmaceuticals (NASDAQ:SUPN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care... 
Via StockStory
Topics Artificial Intelligence Lawsuit
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals
SUPERNUS PHARMACEUTICALS (NASDAQ:SUPN) is an undervalued stock with strong profitability, no debt, and steady growth—making it a potential pick for value investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.